September 2019, Leading Global CRO acquires Genae


genae, Experts in Value-driven Science & Technology for the Medical Industries, today announced the sale to a leading global CRO. Korys invested a first time in genae in 2016, becoming its sole equity partner and has since then been supporting the company along its impressive growth trajectory, boosted by a number of strategic acquisitions. Korys is extremely proud to have been working together with a visionary founding management team who have built out genae into a global reference in its industry. From the start, Korys has been impressed by the long-term perspective of the team and its passion for innovation, quality, customers and patients. Following the acquisition, the combined offerings will enable genae to serve customers with additional technologies and expertise in a space where innovation and data insights are crucial for continued success and sustainable impact on society.

About genae

genae is involved in the development of devices and therapies that change medical practice. With HQ in Antwerp, Belgium, and offices globally, genae serves a client base ranging from publicly traded, strategic players to very early start-ups.